| Covariate | Covariate Categories | Death | Censored | Total (%) | Median survival days |
| Sex | Male | 63 (34.6) | 119 (65.4) | 182 (49.1) | 155 (140, 161) |
| Female | 73 (38.6) | 116 (61.4) | 189 (50.9) | 159 (143, 161) | |
| TB treatment phase | Intensive phase | 54 (32.5) | 112 (67.5) | 166 (44.7) | 70 (56, 139) |
| Continuation phase | 82 (40) | 123 (60) | 205 (55.3) | 162 (159, 166) | |
| TB type | Pulmonary positive | 6 (4.4) | 131 (95.6) | 137 (36.9) | 161 (157, 163) |
| Pulmonary negative | 63 (58.3) | 45 (41.7) | 108 (29.1) | 147 (131, 161) | |
| Extra pulmonary | 67 (53.2) | 59 (46.8) | 126 (34) | 148 (130, 160) | |
| TB category | New | 109 (36.7) | 188 (63.3) | 297 (80.1) | 157 (150, 161) |
| Relapse | 22 (38.6) | 35 (61.4) | 57 (15.4) | 167 (125, 185) | |
| Failure | 3 (33.3) | 6 (66.7) | 9 (2.4) | 121 (49, 169) | |
| Defaulter | 2 (25) | 6 (75) | 8 (2.2) | 158 (1, 169) | |
| Previous TB status | Yes | 32 (43.2) | 42 (56.8) | 74 (19.9) | 169 (148,180) |
| No | 104 (35.0) | 193 (65) | 297 (80.1) | 155 (143,160) | |
| Baseline smear results | Positive | 48 (21.8) | 172 (78.2) | 220 (59.3) | 159 (154, 161) |
| Negative | 88 (58.3) | 63 (41.7) | 151 (40.7) | 153 (132, 162) | |
| HIV infection | Positive | 59 (37.8) | 97 (62.2) | 156 (42) | 154 (137, 161) |
| Negative | 77 (35.8) | 138 (64.2) | 215 (58) | 159 (153, 161) | |
| Presence of co-morbidity | Yes | 54 (34.6) | 102 (65.4) | 156 (42) | 140 (132, 155) |
| No | 82 (38.1) | 133 (61.9) | 215 (58) | 160 (156, 162) | |
| Presence DM | Yes | 19 (45.2) | 23 (54.8) | 42 (11.3) | 161 (136, 180) |
| No | 117 (35.6) | 212 (64.4) | 329 (88.7) | 156 (146, 160) | |
| Presence cancer | Yes | 7 (38.9) | 11 (61.1) | 18 (4.9) | 167 (75, 180) |
| No | 129 (36.5) | 224 (63.5) | 353 (95.1) | 156 (146, 160) | |
| Presence anemia | Yes | 17 (48.6) | 18 (51.4) | 35 (9.4) | 180 (139, 180) |
| No | 119 (35.4) | 217 (64.6) | 336 (90.6) | 155 (144, 160) | |
| Total | 136 (36.7) | 235 (63.3) | 371 (100) | 157 (148, 160) | |